Procept BioRobotics stock rating reiterated at Buy by TD Cowen

TD Cowen reiterated a Buy on PROCEPT BioRobotics with a $34 price target, above the current $25.12 share price and the broader analyst range of $20 to $37. The firm said recent guidance still looks achievable after a difficult fourth quarter and 2026 guidance cut, and expects an in-line first quarter ahead of earnings on April 29. Separately, PROCEPT launched its HYDROS Robotic System in the UK and added Daniel Puckett to its board, supporting international expansion and governance strength.

Analysis

The setup here is less about the new target and more about whether the business is exiting the quarter with its order funnel intact after management changed commercial tactics. If first-quarter procedure growth simply tracks in line, the market can re-rate the name because the prior selloff appears to have priced in a much worse demand inflection than the current operating reality. That creates a classic asymmetry: limited upside to a heroic beat, but meaningful downside if the company needs to cut again.

The real second-order winner is the balance-sheet optionality around international expansion. Early launches outside the U.S. can matter disproportionately for an installed-base platform because even modest overseas utilization helps de-risk the growth curve and improves visibility on future procedure volume; that is especially valuable when domestic sentiment is fragile. Competitively, this is more important for capital equipment peers than for consumable-only medtech names, because any sign of durable adoption can revive hospital budgeting confidence for robotics-adjacent spend.

The main risk is timing. A one-quarter stabilization does not fix the longer-duration issue of whether demand was pulled forward by prior sales behavior, so the stock could still fade if the April print is merely good enough rather than truly reaccelerating. The contrarian view is that consensus may be underestimating how quickly sentiment can normalize if management stops leaning on quarter-end tactics and simply demonstrates clean execution; in this setup, narrative repair can drive the next 10-15% move faster than fundamentals alone would imply.

Key Decisions for Investors

• Go long PRCT into the April 29 earnings print with a 2-3 week horizon; best risk/reward is for a modest position sized for a 10-15% upside gap if first-quarter trends are merely in line, with a stop if management signals any renewed guidance risk.
• Use call spreads rather than outright stock for PRCT: buy the nearest 1-2 month 27.5/32.5 call spread to capture a post-earnings re-rating while limiting downside if the quarter is only acceptable rather than strong.
• If already long, trim into strength on any pre-earnings bounce and hold the remainder through the report; the stock’s downside is largest if expectations drift too far ahead of evidence.
• Pair trade idea: long PRCT / short a slower-growth medtech equipment peer with similar valuation sensitivity, betting that sentiment repair and international launch optionality matter more than multiple compression in a cleaner-execution story.
• If the print disappoints, use the first post-earnings flush to re-evaluate for a longer-dated entry only after the market confirms the demand reset; the key is avoiding a value trap before visibility improves.